SynthesisHIV medicine2025
Patient-reported outcomes in clinical trials assessing the effectiveness of cabotegravir + rilpivirine long-acting injections as antiretroviral therapy: A systematic review.
Synthesis in HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Satisfaction and Treatment Burden Among Early Adopters of Long-Acting Injectable Cabotegravir-Rilpivirine With and Without Viremia in Three US Ryan White Clinics.Open forum infectious diseases · 2026Article
- Accelerating Low-Barrier Use of Long-Acting Antiretroviral Therapy to Maximize Impact in People with HIV and Viremia or Adherence Challenges.Current HIV/AIDS reports · 2026Review
- Review
- Patient-Reported Outcomes with Long-Acting Cabotegravir and Rilpivirine in People Living with HIV.Patient preference and adherence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHuman immunodeficiency virus-1 (HIV-1) continues to have a high global burden, with approximately 39.9 million people currently living with the virus. Despite the clinical success of antiretroviral therapy (ART), adherence remains a significant challenge, often due to emotional distress and HIV-related stigma. Long-acting injectables (LAIs) such as the combination of cabotegravir (CAB) and rilpivirine (RPV) have emerged as promising alternatives, reducing the burden of daily pill regimens.
methodsThis systematic review explores the role of CAB + RPV-LA injectables in antiretroviral therapy (ART), with a focus on patient-reported outcomes from five key clinical trials.
resultsFindings reveal that CAB + RPV-LA maintains high levels of viral suppression comparable to daily ART while improving patient satisfaction and quality of life. Meta-analysis of HIV Treatment Satisfaction Questionnaire (HIVTSQc) scores across multiple trials demonstrated consistent positive outcomes, with a mean score of 28.83 out of a possible range from -33 to +33, indicating a substantial improvement in patient satisfaction compared to baseline. Qualitative data highlight the psychological and logistical benefits of LAIs, including reduced stigma and enhanced treatment convenience.
conclusionsThis review underscores the potential of CAB + RPV-LA in improving patient adherence and satisfaction while offering insights for future studies on longer-term outcomes of LAI use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.